Elsevier

Neuropharmacology

Volume 27, Issue 11, November 1988, Pages 1125-1130
Neuropharmacology

Further behavioural evidence for the selective sedative action of zolpidem

https://doi.org/10.1016/0028-3908(88)90007-XGet rights and content

Abstract

Small doses of benzodiazepines stimulate behavioural output in experimental animals in a variety of situations. Zolpidem, which displaces benzodiazepines from their binding sites, however, has been shown to exert preferential sedative activity. In order to investigate whether small doses of zolpidem would also have stimulant effects, the actions of zolpidem and chlordiazepoxide were compared in three procedures which are sensitive to the behavioural-facilitating effects of benzodiazepines in rats. A small dose of chlordiazepoxide (3.0 mg/kg) increased locomotion in an open field whereas a large dose (30 mg/kg) suppressed this behaviour. Zolpidem (0.3–3.0 mg/kg) only decreased locomotion. The effects of both chlordiazepoxide and zolpidem were antagonised by flumazenil. Chlordiazepoxide (2.5–10 mg/kg) increased the intake of food in rats habituated to a daily feeding schedule but similar doses of zolpidem neither increased nor decreased the intake of food. Rates of punished operant responding were increased by chlordiazepoxide (3.0–30 mg/kg) but zolpidem (1.0–4.0 mg/kg) produced no such anti-punishment effect and suppressed responding at the large dose. These results show that zolpidem does not increase behavioural output in situations which are sensitive to the stimulant effects of benzodiazepines and further emphasize the selective sedative activity of this drug.

References (28)

  • S. Arbilla et al.

    Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats

    Naunyn. Schmiedebergs Arch. Pharmac.

    (1985)
  • J. Benavides et al.

    In vivo interaction of zolpidem with central benzodiazepine binding sites (as labelled by 3H-Ro 15-1788) in the mouse brain. Preferential affinity of zolpidem for the ω1 (BZ1) subtype

    J. Pharmac. exp. Ther.

    (1988)
  • D.A. Bennett et al.

    A non benzodiazepine, non sedating potential anxiolytic

    Drug Devel. Res.

    (1984)
  • S.J. Cooper et al.

    Hypertonic saline intake in the rat after administration of 5-HT1A agonists, benzodiazepine partial agonists and zolpidem

  • Cited by (39)

    • Zolpidem-induced changes in activity, metabolism, and anxiety in rats

      2011, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      Zolpidem (Ambien) is a nonbenzodiazepine drug commonly used for the treatment of insomnia. It has been shown to have observable sedative and hypnotic effects in humans (Nicholson and Pascoe, 1986) and animals (Sanger and Zivkovic, 1988). As a hypnotic drug, it works by slowing activity in the brain to allow sleep, and it is used in the temporary treatment of insomnia characterized by difficulties with sleep initiation (Nicholson and Pascoe, 1986; Wilson and Nutt, 2007).

    View all citing articles on Scopus
    View full text